Ascension President and CEO Joseph Impicciche has provided new insight into the strategic rationale behind the health system’s blockbuster joint venture with AmSurg, calling the $13 billion transaction one of the most important moves in the organization’s recent history. Speaking during a January 2026 briefing with investors, bondholders, and major stakeholders, Impicciche described the deal completed in the final quarter of 2025 as a decisive entry into the fast-growing ambulatory surgery market and a powerful platform for long-term physician alignment.

The transaction combines Ascension’s extensive hospital and physician network with AmSurg’s position as one of the nation’s largest operators of ambulatory surgery centers (ASCs). The resulting entity operates more than 350 surgery centers across multiple states, making it one of the dominant players in outpatient procedural care. Impicciche emphasized that the partnership immediately gives Ascension access to high-growth markets where hospital-based surgery is increasingly shifting to lower-cost, more convenient ASC settings.

“Ambulatory surgery is where care is moving,” Impicciche said. “This joint venture allows us to meet patients and physicians where they want to be—outside the hospital walls while maintaining the highest standards of quality and safety that Ascension is known for.”

A key benefit highlighted by the CEO is the strengthened ability to recruit and retain physicians. The AmSurg model is built on physician ownership and governance in many centers, which Impicciche said aligns incentives and fosters deeper clinical partnerships. This is particularly important at a time when physician burnout and competition for talent remain significant challenges across the industry.

The JV is also expected to deliver operational and financial synergies. These include shared supply chain contracts, standardized clinical protocols, centralized revenue cycle management, and stronger payer negotiations due to combined scale. Early internal financials show the partnership contributing positively to Ascension’s margin improvement trajectory, supporting the system’s goal of returning to stronger operating performance in 2026 and beyond.

Impicciche acknowledged that integrating two large organizations presents execution challenges but expressed confidence in the leadership teams and integration framework. He noted that the deal is part of Ascension’s broader strategy to diversify revenue streams, reduce reliance on inpatient care, and build resilience in an environment of ongoing reimbursement pressure and workforce constraints.

The transaction has drawn attention as one of the largest healthcare joint ventures in recent years and is seen by analysts as a bellwether for how legacy hospital systems are adapting to the shift toward outpatient and value-based care models.